StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research report released on Friday morning. The firm issued a sell rating on the medical device company’s stock.
NeuroMetrix Stock Performance
NURO opened at $4.44 on Friday. The stock’s 50 day simple moving average is $3.89 and its 200 day simple moving average is $3.78. NeuroMetrix has a 1 year low of $2.70 and a 1 year high of $11.55.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The medical device company reported ($1.43) earnings per share (EPS) for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%. The company had revenue of $1.32 million for the quarter.
Hedge Funds Weigh In On NeuroMetrix
About NeuroMetrix
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
See Also
- Five stocks we like better than NeuroMetrix
- What is a Bond Market Holiday? How to Invest and Trade
- MarketBeat Week in Review – 4/22 – 4/26
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks Leading the U.S. Agriculture Comeback
- Utilities Stocks Explained – How and Why to Invest in Utilities
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.